CHAUTARA— A large number of women from rural areas in Sindhupalchok are found suffering from various sorts of reproductive health issues including cervical cancer infection.
Generally, rural women in Sindhupalchok do not visit health facilities or health professionals till they become bed-ridden.
Bearing this bitter reality in mind, Chautara Sangachokgadhi Municipality on Monday organised a free health camp at Sangachok, Sangachokgadhi -12, targeting such section of women.
A seven member medical team led by cancer prevention specialist Dr Kishor Pradhananga from the BP Koirala Cancer Hospital, Bharatpur in Chitwan arrived here to conduct a free health camp where 300 women underwent health checkups.
Out of 180 women tested for the cervical cancer, 150 were found contracting infection for the fatal disease and three were diagnosed of living in a window period.
The camp organised by the local government was coordinated by the Thaha Foundation.
Likewise, a total of 202 women underwent checkup for breast cancer and three suspected cases were detected and three had lumps on their breasts.
A total of 2,500 individuals were given health counseling and 200 were provided medicines at free of cost, according to municipality deputy mayor Januka Parajuli.Follow @gorkhapost
Diabetes drug might ease heart failure risk
A new research has showed that the diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure.
According to the findings were published in the New England Journal of Medicine to coincide with their presentation at the annual meeting of the American Heart Association in Chicago, Type 2 diabetics who took Farxiga saw their odds of hospitalization for heart failure drop by 27 percent compared to those who took a placebo.
Farxiga is a type of drug called a SGLT2 inhibitor. The compound is called dapagliflozin.
The study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.
Patients were randomly assigned to take a dummy placebo pill or 10 milligrams of Farxiga each day.
“When it comes to helping our patients control and manage blood glucose, the ‘how’ appears to be as important [as] the ‘how much,” said study author Dr Stephen Wiviott, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston.
“When choosing a therapy, trial results like these can help us make an informed decision about what treatments are not only safe and effective for lowering blood glucose but can also reduce risk of heart and kidney complications,” Wiviott said in a hospital news release.
Taking the drug did not reduce the risk of heart attack, stroke and cardiovascular-related death, the research team noted. However, patients who took the drug did see healthy declines in their blood sugar levels, plus an added bonus: a 27 percent decrease in their risk of hospitalization for heart failure.
Their risk of kidney failure and death from kidney failure also fell, researchers noted.
Two other recent studies of this class of drugs show that they “robustly and consistently improve heart and kidney outcomes in a broad population of patients with diabetes,” Wiviott noted.
With Inputs from HealthDayFollow @gorkhapost